Share This Article:

A randomized controlled trial of ketorolac for prevention of headache related to electroconvulsive therapy

DOI: 10.4236/pst.2013.12002    3,626 Downloads   7,308 Views   Citations

ABSTRACT

Background and Purpose: Headache is one of the most common side effects of electroconvulsive therapy (ECT), with a reported prevalence as high as 45%. Typical pharmacologic measures include aspirin, acetaminophen, or nonsteroidal anti-inflammatory medications. Among the latter, ketorolac may be especially advantageous in that it can be administered intravenously right before a treatment. The primary aim of this study was to measure the efficacy of intravenous ketorolac administration for the prevention of post-ECT headache at the first treatment session. Methods: Sixteen patients were assigned to the control group, while eight patients were assigned to the ketorolac treatment group (8 males, 16 females; mean age ± standard deviation = 46 ± 13.5 years). Statistical analysis consisted of a one-way analysis of variance using the two-sample test. We utilized a post-ECT headache severity scale from zero (no headache) to 3 (severe headache). Results:The mean score for the control group was 1.3 (±1.1), while the mean score for the ketorolac treatment group was 1.2 (±1.1), p = 0.86 (not significant). Conclusions: Ketorolac administration does not decrease the incidence of post ECT headache at the first treatment session. It is possible that ketorolac may be effective at subsequent treatments for patients with particularly bothersome headaches after the first treatment. Implications: Ketorolac should not be routinely used at the first treatment session to prevent headache associated with ECT.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

G. Rasmussen, K. (2013) A randomized controlled trial of ketorolac for prevention of headache related to electroconvulsive therapy. Pain Studies and Treatment, 1, 5-8. doi: 10.4236/pst.2013.12002.

References

[1] American Psychiatric Association (2001) The practice of ECT: Recommendations for treatment, training, and privileging. American Psychiatric Press Inc., Washington DC.
[2] Markowitz, J.S., Kellner, C.H., DeVane, C.L., Beale, M.D., Folk, J., Burns, C. and Liston, H.L. (2001) Intranasal sumatriptan in post-ECT headache: Results of an open-label trial. The Journal of ECT, 17, 280-283. doi:10.1097/00124509-200112000-00008
[3] DeBattista, C. and Mueller, K. (1995) Sumatriptan prophylaxis for postelectroconvulsive therapy headaches. Headache, 35, 502-503. doi:10.1111/j.1526-4610.1995.hed3508502.x
[4] Oms, A., Miro, E. and Rojo, J. (1998) Sumatriptan was effective in electroconvulsive therapy (ECT) headache. Anesthesiology, 89, 1291-1292. doi:10.1097/00000542-199811000-00054
[5] Weiner, S.J., Ward, T.N. and Ravaris, C.L. (1993) Headache and electroconvulsive therapy. Headache, 34, 155- 159. doi:10.1111/j.1526-4610.1994.hed3403155.x

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.